Month: March 2022

Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) — Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting reference date changed from 30 June to 31 December during the year1, therefore these financial statements report on both a 12- and 18-month period. SUMMARY PERFORMANCE£m, unless stated otherwise 12 months ended 31 Dec 2021 (unaudited)(‘CY2021’) 12 months ended 31 Dec 2020 (unaudited)(‘CY2020’) 18 months ended 31 Dec 2021 (audited)Revenue 315.4 269.3 462.9Adjusted...

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

– SPEARHEAD-1 met its primary endpoint – planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma – – Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 in ovarian cancer in 2022 – – Allogeneic platform on-track for planned IND submission in 2023 for first product targeting MAGE-A4 – – Started our strategic collaboration for allogeneic T-cell therapies with Genentech – $150 million upfront payment received – – Scaling up autologous patient supply at Navy Yard facility and construction underway of a dedicated allogeneic cell manufacturing facility in the UK – – Appointed Cintia Piccina as Chief Commercial Officer – – Financial guidance confirmed: funded...

F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

Multiple Clinical Program Updates Expected in 2022 Continued Expansion of Leading Bispecific Antibody IP Estate Two New Significant Partnerships with Janssen and AstraZeneca Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced full-year 2021 financial results and will provide a corporate update. “Bispecifics have come of age, and F-star is exceptionally well positioned in this field with our unique tetravalent bispecific platform,” said Eliot Forster, Chief Executive Officer of F-star Therapeutics. “With all four of our clinical programs poised to...

Ideal Power Appoints Two Independent Members to its Board of Directors

Written by Customer Service on March 14, 2022. Posted in Public Companies.

AUSTIN, Texas, March 14, 2022 (GLOBE NEWSWIRE) — Ideal Power Inc. (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bidirectional power switches, today announced that its Board of Directors (“Board”) appointed two new independent members, Drue Freeman and Greg Knight, to the Board. As a result of these appointments, Ideal Power’s Board will increase in size from three to five members, four of whom are independent. These directors will bring deep expertise in semiconductors and significant experience and relationships in the Company’s initial target markets for B-TRAN™, including electric vehicles (EVs), renewable energy, energy storage and power electronics. “Drue has spent his career in the semiconductor industry, and brings commercial and strategic expertise and...

HCI Group Authorizes $20 Million Stock Repurchase Program for 2022

Written by Customer Service on March 14, 2022. Posted in Public Companies.

TAMPA, Fla., March 14, 2022 (GLOBE NEWSWIRE) — The board of directors of HCI Group, Inc. (NYSE:HCI), a holding company primarily engaged in homeowners insurance, with additional operations in reinsurance, real estate and information technology, has authorized a plan to repurchase up to $20 million of the company’s common shares during 2022, subject to market conditions. The plan permits the company to periodically repurchase shares for cash in open market purchases, block transactions and privately negotiated transactions in accordance with applicable federal securities laws. Moreover, the share repurchase plan may be modified, suspended, terminated or extended by the company any time without prior notice. About HCI Group, Inc.HCI Group, Inc. owns subsidiaries engaged in diverse, yet complementary business activities, including...

ICU Medical, Inc. to Participate at the KeyBanc Life Sciences & MedTech Investor Forum

Written by Customer Service on March 14, 2022. Posted in Public Companies.

SAN CLEMENTE, Calif., March 14, 2022 (GLOBE NEWSWIRE) — ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that company management will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 8:15 a.m. PT (11:15 a.m. ET) on Tuesday, March 22, 2022. Company management will also be participating in one-on-one meetings on Tuesday, March 22, 2022. The fireside chat will be webcast live and can be accessed by going to the company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay. About ICU Medical, Inc. ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion consumables, and high-value critical...

Reed’s Inc.® Announces Closing of $5.4 Million Private Placement

Written by Customer Service on March 14, 2022. Posted in Public Companies.

NORWALK, Conn., March 14, 2022 (GLOBE NEWSWIRE) — Reed’s, Inc.® (NASDAQ:REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, all-natural ginger beverages, today announced the closing of its previously announced private placement with certain institutional and accredited investors of 18,594,571 shares of common stock and warrants to purchase up to an aggregate of 9,297,289 shares of common stock, for an aggregate gross proceeds of $5.4 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. Officers and directors of the Company purchased approximately $1.1 million of the securities in the offering. The purchase price per share of common stock and associated warrant was $0.28 for the investors (other than officers and directors of the Company)...

EXL named a Leader and Star Performer in Everest Group’s Healthcare Payer Operations PEAK Matrix® Assessment 2022

Written by Customer Service on March 14, 2022. Posted in Public Companies.

NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a leading global analytics and digital solutions company, announced today that it has been named a Leader and Star Performer in Everest Group’s Healthcare Payer Operations PEAK Matrix® Assessment 2022. EXL advanced to a Leader from the Major Contender category in last year’s PEAK MATRIX® Assessment, reflecting the company’s continued growth in analytics and digital solutions, and its commitment to helping clients make sense of data to drive their businesses forward. Everest Group cites EXL’s strong analytics capabilities and domain knowledge as its greatest strengths. “After a brief pause due to the COVID-19 pandemic, the healthcare payer market is again witnessing investments by enterprises in digital technologies, such as analytics and cognitive automation, especially...

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Written by Customer Service on March 14, 2022. Posted in Public Companies.

DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID-19, met to evaluate the clinical and safety data from the first planned interim analysis. Following their evaluation, the DSMB recommended that the study continue without modification. “We continue to be pleased with the conduct of the trial and look forward to the next DSMB meeting currently planned for May,” said Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals. About the Phase 2/3 Clinical Trial Additional information about the trial...

Allegiant Gold Announces a C$4.0 Million Strategic Investment by Kinross Gold Corporation for Exploration at the Eastside Property

Written by Customer Service on March 14, 2022. Posted in Public Companies.

RENO, Nev., March 14, 2022 (GLOBE NEWSWIRE) — Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is pleased to announce a C$4,014,404 financing and strategic investment by Kinross Gold Corporation (“Kinross”) (NYSE: KGC, TSX: K) which will accelerate the exploration and development activities at the Eastside property in Nevada. On closing Kinross will own 9.9% of the then issued shares of Allegiant. Kinross operates the Round Mountain gold mine, located across the valley from Allegiant’s Eastside project. Round Mountain is one of the largest open pit gold mines in the United States. Peter Gianulis, CEO of Allegiant Gold, commented: “We are very excited to have Kinross as a strategic partner, given their experience and prominent presence in Nevada, and the relative close proximity of their flagship Round...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals